Johnson & Johnson's big-selling Remicade has held most of its ground against biosimilar competition, thanks in part to some aggressive payer contracts that rivals—including Pfizer—have called into ...
Two pharma giants are squaring off a first-of-a-kind lawsuit over the budding biosimilar business in the U.S. Unable to make much headway with its first biosimilar rollout, Pfizer accuses Johnson & ...
Remicade comes as a powder. A healthcare professional mixes the powder with liquid to form a solution, which they give as an intravenous (IV) infusion. (This is an injection into a vein given over ...
Johnson & Johnson’s Remicade, which remains one of the world’s best-selling drugs, is one step closer to facing competition after a FDA advisory committee voted 21-3 in support of approving a ...
In a recent development with the ongoing complex litigation involving Janssen Biotech’s arthritis biologic medicine Remicade (infliximab) and Celltrion’s biosimilar,[1] Celltrion’s partner Pfizer has ...
Inflammatory bowel disease (IBD) is a serious digestive disease of the small intestine and colon; and includes Crohn’s disease and ulcerative colitis. Now, doctors are testing a new use for an ...
The District Court for the Eastern District of Pennsylvania has denied Johnson & Johnson and Janssen’s (“J&J”) motion to dismiss antitrust claims filed by Walgreens and Kroger concerning sales of ...
PHILADELPHIA, PA, October 15, 2007- Clinical data presented today at the annual meeting of the American College of Gastroenterology (ACG) show that REMICADE significantly reduces the incidence of ...
SAN ANTONIO, TX, February 1, 2008 -- Data from an integrated analysis of three randomized, placebo-controlled trials showed patients with moderate to severe plaque psoriasis receiving REMICADE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results